URGN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
72.5M
+42.2%
51.0M
+34.7%
37.8M
+37.7%
27.5M
+13.5%
24.2M
Cost of Revenue
6.6M
+58.8%
4.1M
+25.8%
3.3M
+0.3%
3.3M
-7.7%
3.5M
Gross Profit
65.9M
+40.7%
46.8M
+35.5%
34.5M
+42.7%
24.2M
+17.1%
20.7M
Operating Expenses
65.8M
-2.0%
67.1M
+25.0%
53.7M
+4.0%
51.6M
-16.9%
62.1M
R&D
17.3M
+11.1%
15.6M
+9.0%
14.3M
+2.2%
14.0M
-25.9%
18.9M
SG&A
48.4M
-5.9%
51.5M
+30.8%
39.3M
+4.7%
37.6M
-13.0%
43.2M
Operating Income
111.0K
+100.5%
-20263000
-6.0%
-19115000
+30.2%
-27386000
+33.9%
-41448000
EBITDA
189.0K
+100.9%
-20188000
-6.0%
-19040000
+30.3%
-27306000
+34.0%
-41368000
Net Income
-14351000
+39.1%
-23574000
+10.6%
-26364000
+20.9%
-33347000
+33.2%
-49940000
EPS (Basic)
$-0.28
+40.4%
$-0.47
+13.0%
$-0.54
+21.7%
$-0.69
+34.3%
$-1.05
EPS (Diluted)
$-0.28
+40.4%
$-0.47
+13.0%
$-0.54
+21.7%
$-0.69
+34.3%
$-1.05
Shares (Diluted)
50.4M
+0.4%
50.2M
+1.9%
49.2M
+2.5%
48.1M
+0.7%
47.7M
UroGen Pharma (URGN) โ€” Financials